WHO announces plans to back weight-loss drugs to address global obesity crisis
The World Health Organization (WHO) has made a groundbreaking announcement in the fight against the global obesity epidemic. In a recent memo, the agency revealed its support for weight-loss drugs in adults worldwide, specifically backing GLP-1s like Wegovy and Zepbound as effective treatments for obesity.
According to WHO data, more than one billion people around the world are affected by obesity, with 70% of these individuals residing in low- and middle-income countries. Recognizing the urgent need to address this public health crisis, WHO is advocating for strategies to improve access to weight-loss medications in these regions.
While GLP-1 drugs have shown promising results in high-income countries like the U.S., Britain, and Germany, cost remains a significant barrier for many individuals. With some medications priced at over $1,000 per month, affordability continues to be a concern for those seeking effective weight-loss solutions.
In response to the growing demand for obesity treatments, WHO is developing a set of new recommendations for prevention, care, and treatment across different age groups. These guidelines are expected to be finalized by August or September 2025, outlining how weight-loss medications can be integrated into a comprehensive chronic care model that combines clinical and lifestyle interventions.
Furthermore, WHO experts will convene next week to assess whether GLP-1 drugs should be included on the agency’s list of essential medications for both obesity and type 2 diabetes. In addition, the agency is calling for long-term studies to evaluate the cost-effectiveness of these drugs in various settings and income levels.
As the global obesity crisis continues to escalate, WHO’s support for weight-loss drugs represents a crucial step forward in combating this widespread health issue. By prioritizing access to effective treatments and developing comprehensive guidelines for obesity management, WHO is leading the charge in promoting healthier lifestyles and reducing the burden of obesity on individuals and communities worldwide.
